SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03239145

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: - Pembrolizumab - AMG386

NCT03239145 Advanced Solid Tumor

2 Interventions

Name: Pembrolizumab

Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells

Type: Drug

Pembrolizumab + Trebananib Pembrolizumab + Trebananib (Melanoma) Pembrolizumab + Trebananib (Ovarian) Pembrolizumab + Trebananib (Colorectal) Pembrolizumab + Trebananib (Renal Cell Carcinoma)

Name: Trebananib

Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen

Type: Drug

Pembrolizumab + Trebananib Pembrolizumab + Trebananib (Melanoma) Pembrolizumab + Trebananib (Ovarian) Pembrolizumab + Trebananib (Colorectal) Pembrolizumab + Trebananib (Renal Cell Carcinoma)


Primary Outcomes

Measure: Dose Limiting Toxicity

Time: 2 years

Secondary Outcomes

Measure: Objective Response Rate

Time: 2 years

Measure: Progression Free Survival

Time: 2 years

Measure: Overall Survival

Time: 2 years

Purpose: Treatment

Allocation: Non-Randomized

Parallel Assignment


There are 2 SNPs

SNPs


1 V600E

Melanoma patients with BRAF V600E or V600K mutation-positive melanoma who have previously received a BRAF inhibitor with or without a MEK inhibitor) are eligible. --- V600E ---


2 V600K

Melanoma patients with BRAF V600E or V600K mutation-positive melanoma who have previously received a BRAF inhibitor with or without a MEK inhibitor) are eligible. --- V600E --- --- V600K ---



HPO Nodes